Skip Nav Destination
Content Menu
-
Abstract
623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models| December 6, 2014
Erden Atilla, MD,
Erden Atilla, MD *
1Ankara University Faculty of Medicine, Ankara, Turkey
Search for other works by this author on:
This Site
Ugur Sahin, MD,
Ugur Sahin, MD *
1Ankara University Faculty of Medicine, Ankara, Turkey
Search for other works by this author on:
This Site
Pinar Ataca, MD,
Pinar Ataca, MD *
1Ankara University Faculty of Medicine, Ankara, Turkey
Search for other works by this author on:
This Site
Atilla Uslu, MD,
Atilla Uslu, MD *
2Ankara University Faculty of Medicine, Ankara, Turkey
Search for other works by this author on:
This Site
Ekin Kircali, MD,
Ekin Kircali, MD *
2Ankara University Faculty of Medicine, Ankara, Turkey
Search for other works by this author on:
This Site
Berna Atesagaoglu, MD,
Berna Atesagaoglu, MD *
1Ankara University Faculty of Medicine, Ankara, Turkey
Search for other works by this author on:
This Site
Gultekin Pekcan, MD,
Gultekin Pekcan, MD *
1Ankara University Faculty of Medicine, Ankara, Turkey
Search for other works by this author on:
This Site
Mustafa Merter, MD,
Mustafa Merter, MD *
1Ankara University Faculty of Medicine, Ankara, Turkey
Search for other works by this author on:
This Site
Mehmet Gunduz, MD,
Mehmet Gunduz, MD *
1Ankara University Faculty of Medicine, Ankara, Turkey
Search for other works by this author on:
This Site
Mehmet Ozen, MD,
Mehmet Ozen, MD *
1Ankara University Faculty of Medicine, Ankara, Turkey
Search for other works by this author on:
This Site
Sinem Civriz Bozdag, MD,
Sinem Civriz Bozdag, MD *
1Ankara University Faculty of Medicine, Ankara, Turkey
Search for other works by this author on:
This Site
Selami Kocak Toprak, MD,
Selami Kocak Toprak, MD *
1Ankara University Faculty of Medicine, Ankara, Turkey
Search for other works by this author on:
This Site
Pervin Topcuoglu, MD,
Pervin Topcuoglu, MD *
1Ankara University Faculty of Medicine, Ankara, Turkey
Search for other works by this author on:
This Site
Onder Arslan, MD,
Onder Arslan, MD *
1Ankara University Faculty of Medicine, Ankara, Turkey
Search for other works by this author on:
This Site
Taner Demirer, MD,
Taner Demirer, MD *
1Ankara University Faculty of Medicine, Ankara, Turkey
Search for other works by this author on:
This Site
Hamdi Akan, MD,
Hamdi Akan, MD *
1Ankara University Faculty of Medicine, Ankara, Turkey
Search for other works by this author on:
This Site
Gunhan Gurman, MD,
Gunhan Gurman, MD *
1Ankara University Faculty of Medicine, Ankara, Turkey
Search for other works by this author on:
This Site
Meral Beksac, MD,
Meral Beksac, MD
1Ankara University Faculty of Medicine, Ankara, Turkey
Search for other works by this author on:
This Site
Osman Ilhan, MD,
Osman Ilhan, MD *
1Ankara University Faculty of Medicine, Ankara, Turkey
Search for other works by this author on:
This Site
Nahide Konuk, MD,
Nahide Konuk, MD *
1Ankara University Faculty of Medicine, Ankara, Turkey
Search for other works by this author on:
This Site
Muhit Ozcan, MD
Muhit Ozcan, MD
1Ankara University Faculty of Medicine, Ankara, Turkey
Search for other works by this author on:
This Site
Blood (2014) 124 (21): 5448.
- Split-Screen
- Tools Icon Tools
Cite Icon Cite
- Search Site
Citation
Erden Atilla, Ugur Sahin, Pinar Ataca, Atilla Uslu, Ekin Kircali, Berna Atesagaoglu, Gultekin Pekcan, Mustafa Merter, Mehmet Gunduz, Mehmet Ozen, Sinem Civriz Bozdag, Selami Kocak Toprak, Pervin Topcuoglu, Onder Arslan, Taner Demirer, Hamdi Akan, Gunhan Gurman, Meral Beksac, Osman Ilhan, Nahide Konuk, Muhit Ozcan; Is R-CODOX-M/IVAC Inferior to Other Regimens in Burkitt’s Lymphoma: A Single Center Experience. Blood 2014; 124 (21): 5448. doi: https://doi.org/10.1182/blood.V124.21.5448.5448
Download citation file:
- Ris (Zotero)
- Reference Manager
- EasyBib
- Bookends
- Mendeley
- Papers
- EndNote
- RefWorks
- BibTex
Abstract
INTRODUCTION: Though widely used and accepted as a first line regimen, published data regarding R-CODOX-M/IVAC is very limited. Up to date only three prospective studies and one case series have been reported. Herein, we present our institution’s experience with the management of Burkitt’s lymphoma with a special emphasis on the R-CODOX-M/IVAC regimen.
METHODS: The files and electronic records of 35 patients diagnosed with Burkitt’s lymphoma between January 2005 and June 2014 were retrospectively revised.
RESULTS: The median age at diagnosis was 40 (21-86 years). Male patients constituted 71.4 (n=25). Stage IV disease was present in 60.6% (n=20), and stage I disease in 27.3% (n=9) of the patients. ECOG performance scoring was < 3 in 70.6% (n=24) and Burkitt’s lymphoma risk scoring (availability of complete surgical resection, stage, serum LDH and CNS involvement) > 2 in 58.6% (n=17). The distribution of patients to administered regimens were as follows: R-CODOX-M/IVAC 10 patients (28.6%), HyperCVAD 5 patients (14.3%), R-CHOP 9 patients (25.7%), R-CVP 2 patients (5.7%), CALGB 10002 1 patient (2.9%) and other regimens (high dose methotrexate, high dose cytarabine, vincristine-prednisolone, etc.) 8 patients (23.0%). Median overall survival (OS) was 23.5 (1-114) months and median progression free survival was 17.0 (0-114) months. Relapses occurred in 7 patients (20.0%), mortality in 12 patients (34.3).
R-CODOX-M/IVAC group (n=10) was compared to other rituximab containing regimens (R-CHOP, R-CVP) (n=11) and HyperCVAD (n=5) and other rituximab-free regimens (n=9) with respect to patient and disease characteristics, DFS and OS. The disease stage, ECOG performance score and Burkitt’s lymphoma risk score were similar between the four groups (p=0.6, p=0.2 and p=0.2, respectively). However, median OS was 13 (1-42) months in R-CODOX-M/IVAC group and it was significantly lower than other regimens (p=0.04 log rank test). Median PFS was 13 (0-42) months and also lower compared to other regimens, however, the difference was not statistically significant (p=0,1 log rank test).
CONCLUSIONS: Burkitt’s lymphoma is currently one of the most aggressive mature B- cell origin lymphomas and there is no consensus on the standard of care. CODOX-M/ IVAC is one of the most frequently used regimen. Adding rituximab is also known to prolong overall survival in this patient population. Though the sample sizes are too small and the drawbacks of the retrospective study design exist, the inferior OS and PFS observed in this study with R-CODOX-M within patients having similar disease characteristics should be taken into account. Further studies comparing the efficiency of currently used regimens are needed to reach a clear conclusion.
Figure 1
View largeDownload slide
Figure 1
View largeDownload slide
Close modal
Figure 2
View largeDownload slide
Figure 2
View largeDownload slide
Close modal
Disclosures
No relevant conflicts of interest to declare.
Topics:
burkitt's lymphoma, rituximab, electrocorticogram, hypercvad protocol, r-chop, cytarabine, excision, lactate dehydrogenase test, serum, lymphoma, methotrexate
Author notes
*
Asterisk with author names denotes non-ASH members.
© 2014 by The American Society of Hematology
2014
Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email.
Comment not saved. Please try again.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal
December 6 2014
- Previous Article
- Next Article
Advertisem*nt
View Metrics
Cited By
Google Scholar
Email alerts
Article Activity Alert
First Edition Alert
Latest Issue Alert
Close Modal
Advertisem*nt
